Liminal Biosciences Inc. (LMNL): Price and Financial Metrics


Liminal Biosciences Inc. (LMNL): $0.50

0.00 (-0.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LMNL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LMNL Stock Summary

  • LMNL's current price/earnings ratio is 3.55, which is higher than only 2.9% of US stocks with positive earnings.
  • Revenue growth over the past 12 months for Liminal BioSciences Inc comes in at -81.22%, a number that bests only 1.37% of the US stocks we're tracking.
  • The volatility of Liminal BioSciences Inc's share price is greater than that of 97.47% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Liminal BioSciences Inc are ESPR, CLPT, EYPT, WB, and JAGX.
  • LMNL's SEC filings can be seen here. And to visit Liminal BioSciences Inc's official web site, go to www.liminalbiosciences.com.

LMNL Price Target

For more insight on analysts targets of LMNL, see our LMNL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.68 Average Broker Recommendation 2.12 (Hold)

LMNL Stock Price Chart Interactive Chart >

Price chart for LMNL

LMNL Price/Volume Stats

Current price $0.50 52-week high $6.30
Prev. close $0.50 52-week low $0.37
Day low $0.49 Volume 11,822
Day high $0.50 Avg. volume 60,449
50-day MA $0.80 Dividend yield N/A
200-day MA $1.35 Market Cap 15.37M

Liminal Biosciences Inc. (LMNL) Company Bio


Liminal Biosciences Inc. operates as a bio-pharmaceutical company. The Company, through its subsidiaries, researches, develops, manufactures, and markets a variety of commercial applications from its core technology. Liminal's applications are used in therapeutics, large-scale drug purification, chemical genomics and proteomics, and drug development.


LMNL Latest News Stream


Event/Time News Detail
Loading, please wait...

LMNL Latest Social Stream


Loading social stream, please wait...

View Full LMNL Social Stream

Latest LMNL News From Around the Web

Below are the latest news stories about Liminal BioSciences Inc that investors may wish to consider to help them evaluate LMNL as an investment opportunity.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agile Therapeutics (AGRX), Argenx Se (ARGX) and Liminal BioSciences (LMNL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agile Therapeutics (AGRX – Research Report), Argenx Se (ARGX – Research Report) and Liminal BioSciences (LMNL – Research Report). Agile Therapeutics (AGRX) In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics, with a price target of $2.50. The company's shares closed last Wednesday at $0.34, close to its 52-week low of $0.34. According to TipRanks.

Catie Powers on TipRanks | January 20, 2022

Liminal BioSciences Announces Strategic Priorities For 2022

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate and research and development priorities for 2022.

Yahoo | January 19, 2022

Liminal BioSciences Reports Third Quarter 2021 Financial Results

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the third quarter ended September 30, 2021.

Yahoo | November 15, 2021

Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | November 4, 2021

Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the remainder of the Company's plasma-derived therapeutics business (the "Second Closing") under the terms of the previously-announced Share Purchase Agreement entered into by the Company and Kedrion S.p.A. ("Kedrion").

Yahoo | October 15, 2021

Read More 'LMNL' Stories Here

LMNL Price Returns

1-mo -35.90%
3-mo -43.70%
6-mo -59.68%
1-year -88.12%
3-year -98.71%
5-year -99.97%
YTD -54.13%
2021 -74.05%
2020 -49.88%
2019 -95.69%
2018 -81.28%
2017 -37.82%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8296 seconds.